BG60450B2 - Фармацевтичен състав - Google Patents
Фармацевтичен състав Download PDFInfo
- Publication number
- BG60450B2 BG60450B2 BG052984A BG5298481A BG60450B2 BG 60450 B2 BG60450 B2 BG 60450B2 BG 052984 A BG052984 A BG 052984A BG 5298481 A BG5298481 A BG 5298481A BG 60450 B2 BG60450 B2 BG 60450B2
- Authority
- BG
- Bulgaria
- Prior art keywords
- water
- guanine
- composition according
- hydroxyethoxymethyl
- ester
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 21
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 239000008346 aqueous phase Substances 0.000 claims abstract description 8
- 239000012071 phase Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 5
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 5
- 235000019737 Animal fat Nutrition 0.000 claims abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 22
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- -1 propylene glycol diester Chemical class 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 5
- 229940057995 liquid paraffin Drugs 0.000 claims description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 239000010695 polyglycol Substances 0.000 claims description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 claims description 2
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 claims description 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940078545 isocetyl stearate Drugs 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 229940043348 myristyl alcohol Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 claims 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 239000006071 cream Substances 0.000 description 11
- 239000013543 active substance Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8023645 | 1980-07-18 | ||
| GB8033218A GB2080106B (en) | 1980-07-18 | 1980-10-15 | Acyclovin preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG60450B2 true BG60450B2 (bg) | 1995-04-28 |
Family
ID=26276273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG052984A BG60450B2 (bg) | 1980-07-18 | 1981-07-17 | Фармацевтичен състав |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0044543B1 (de) |
| AR (1) | AR225680A1 (de) |
| AT (1) | AT381025B (de) |
| AU (1) | AU547391B2 (de) |
| BG (1) | BG60450B2 (de) |
| CA (1) | CA1172169A (de) |
| CS (1) | CS229674B2 (de) |
| CY (1) | CY1309A (de) |
| DD (1) | DD203464A5 (de) |
| DE (1) | DE3163982D1 (de) |
| DK (1) | DK149191C (de) |
| ES (1) | ES504046A0 (de) |
| FI (1) | FI76255C (de) |
| GB (1) | GB2080106B (de) |
| GR (1) | GR75104B (de) |
| HK (1) | HK95485A (de) |
| HU (1) | HU185936B (de) |
| IE (1) | IE51120B1 (de) |
| IL (1) | IL63351A (de) |
| IT (1) | IT1171399B (de) |
| MC (1) | MC1408A1 (de) |
| MY (1) | MY8600389A (de) |
| NO (1) | NO155038C (de) |
| NZ (1) | NZ197744A (de) |
| PH (1) | PH16308A (de) |
| PL (1) | PL135416B1 (de) |
| PT (1) | PT73391B (de) |
| RO (1) | RO82678A (de) |
| SG (1) | SG72085G (de) |
| ZW (1) | ZW17181A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0095813A3 (de) * | 1982-06-01 | 1985-05-08 | THE PROCTER & GAMBLE COMPANY | Durchdringende topische pharmazeutische Präparate, die 9-(2-Hydroxyäthoxymethyl)-guanin enthalten |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| GB8602346D0 (en) * | 1986-01-30 | 1986-03-05 | Wellcome Found | Antiviral combinations |
| GB8917959D0 (en) * | 1989-08-05 | 1989-09-20 | Beecham Group Plc | Pharmaceutical formulation |
| GB9001886D0 (en) * | 1990-01-26 | 1990-03-28 | Beecham Group Plc | Pharmaceutical formulation |
| US6469015B1 (en) | 1990-01-26 | 2002-10-22 | Novartis International Pharmaceutical Ltd | Pharmaceutical formulation |
| EP0773091A3 (de) * | 1992-03-20 | 1998-04-01 | Unichema Chemie B.V. | Formtrennzusammensetzung |
| DK169121B1 (da) * | 1992-09-09 | 1994-08-22 | Gea Farmaceutisk Fabrik As | Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf |
| DE4416674C2 (de) * | 1994-05-11 | 1997-01-30 | Rentschler Arzneimittel | Topische Zubereitung enthaltend Aciclovir |
| DE19517147C2 (de) * | 1995-05-10 | 1999-07-01 | Hexal Pharmaforschung Gmbh | Aciclovir-Zubereitung |
| WO1997034607A1 (en) * | 1996-03-20 | 1997-09-25 | Glaxo Group Limited | Topical formulations of aciclovir |
| GB9611167D0 (en) * | 1996-05-29 | 1996-07-31 | Glaxo Group Ltd | Medicaments |
| GB9718568D0 (en) | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| GB9718791D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Medicaments |
| ITMI981528A1 (it) * | 1998-07-03 | 2000-01-03 | Recordati Ind Chimica E Farma | Formulazioni topiche di aciclovir |
| US7223387B2 (en) | 1998-11-18 | 2007-05-29 | Medivir Ab | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| GB9828620D0 (en) * | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Medicaments |
| FR2837102B1 (fr) * | 2002-03-18 | 2004-10-08 | Palbian Snc | Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique |
| US8697712B2 (en) * | 2004-04-05 | 2014-04-15 | Laboratorios Liomont, S.A. De C.V. | Presentation of an antiviral pharmaceutical composition |
| EP2005824A1 (de) † | 2007-06-21 | 2008-12-24 | Bayer CropScience AG | Wirkstoffsuspensionen in Glycerin |
| WO2017029298A1 (en) | 2015-08-17 | 2017-02-23 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A topical antiviral composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3892857A (en) * | 1972-11-24 | 1975-07-01 | Squibb & Sons Inc | Steroid formulation |
| ZA738657B (en) * | 1973-01-05 | 1974-10-30 | Hoffmann La Roche | Emulsions |
| GB1478009A (en) * | 1973-04-02 | 1977-06-29 | Glaxo Lab Ltd | Pharmaceutical compositions |
| US4199574A (en) * | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
| GB1543907A (en) * | 1975-02-19 | 1979-04-11 | Dermal Labor Ltd | Steroid compositions |
| US3934013A (en) * | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
| US4049802A (en) * | 1975-03-19 | 1977-09-20 | Research Corporation | Zinc sulfadiazine and its use in the treatment of burns |
| GB1554720A (en) * | 1975-07-10 | 1979-10-24 | Nyegaard & Co As | Pyridthione derivatives |
| US4144332A (en) * | 1976-01-05 | 1979-03-13 | The Regents Of The University Of Michigan | Process for alleviating proliferative skin diseases |
| DE2847975A1 (de) * | 1978-11-04 | 1980-05-14 | Merck Patent Gmbh | Verfahren zur bindung von freiem formaldehyd in pharmazeutischen und kosmetischen zubereitungen |
-
1980
- 1980-10-15 GB GB8033218A patent/GB2080106B/en not_active Expired
-
1981
- 1981-07-17 NZ NZ197744A patent/NZ197744A/xx unknown
- 1981-07-17 PL PL1981232259A patent/PL135416B1/pl unknown
- 1981-07-17 IT IT48925/81A patent/IT1171399B/it active Protection Beyond IP Right Term
- 1981-07-17 MC MC811529A patent/MC1408A1/xx unknown
- 1981-07-17 DD DD81231891A patent/DD203464A5/de unknown
- 1981-07-17 IL IL63351A patent/IL63351A/xx not_active IP Right Cessation
- 1981-07-17 CA CA000381977A patent/CA1172169A/en not_active Expired
- 1981-07-17 PH PH25929A patent/PH16308A/en unknown
- 1981-07-17 ZW ZW171/81A patent/ZW17181A1/xx unknown
- 1981-07-17 PT PT73391A patent/PT73391B/pt unknown
- 1981-07-17 DK DK321681A patent/DK149191C/da active
- 1981-07-17 GR GR65549A patent/GR75104B/el unknown
- 1981-07-17 DE DE8181105635T patent/DE3163982D1/de not_active Expired
- 1981-07-17 ES ES504046A patent/ES504046A0/es active Granted
- 1981-07-17 HU HU812097A patent/HU185936B/hu not_active IP Right Cessation
- 1981-07-17 IE IE1617/81A patent/IE51120B1/en not_active IP Right Cessation
- 1981-07-17 FI FI812257A patent/FI76255C/fi not_active IP Right Cessation
- 1981-07-17 CY CY1309A patent/CY1309A/xx unknown
- 1981-07-17 AR AR286131A patent/AR225680A1/es active
- 1981-07-17 CS CS815507A patent/CS229674B2/cs unknown
- 1981-07-17 AT AT0318081A patent/AT381025B/de not_active IP Right Cessation
- 1981-07-17 AU AU73073/81A patent/AU547391B2/en not_active Expired
- 1981-07-17 BG BG052984A patent/BG60450B2/bg unknown
- 1981-07-17 NO NO812464A patent/NO155038C/no unknown
- 1981-07-17 EP EP81105635A patent/EP0044543B1/de not_active Expired
-
1982
- 1982-07-17 RO RO82104911A patent/RO82678A/ro unknown
-
1985
- 1985-10-05 SG SG720/85A patent/SG72085G/en unknown
- 1985-11-28 HK HK954/85A patent/HK95485A/xx not_active IP Right Cessation
-
1986
- 1986-12-30 MY MY389/86A patent/MY8600389A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG60450B2 (bg) | Фармацевтичен състав | |
| NL193419C (nl) | Topicaal toepasbare farmaceutische samenstellingen. | |
| US4963555A (en) | Formulations of heterocyclic compounds | |
| JP3947215B2 (ja) | 安定な局所レチノイド組成物 | |
| KR920021139A (ko) | 약학 조성물 | |
| EP0007595B1 (de) | Clotrimazolpräparate und Verfahren zu deren Herstellung | |
| EP0662819B1 (de) | Antiviral wirksame pharmazeutische öl in wasser-emulsion, die 9-[(2-hydroxyethoxy)methyl]-guanin (acyclovir) oder ein salz oder einen ester davon enthält | |
| EP0471084B1 (de) | Wässerige emulsion mit nicht steroidhaltigen entzündungshemmenden schmerzmitteln | |
| US7223387B2 (en) | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester | |
| AP197A (en) | Pharmaceutical formulations for treatment of virus infections of the skin containing penciclovir. | |
| CA2351463C (en) | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester | |
| PT100670B (pt) | Formulacoes farmaceuticas topicas de oleo-em -agua ou aquosa para o tratamento de infeccoes virais | |
| IE902819A1 (en) | Pharmaceutical formulation | |
| JPH0699304B2 (ja) | ３―オキシゲルミルプロピオン酸を有効成分とする外用剤 | |
| WO1997045123A1 (en) | Topical pharmaceutical formulations comprising aciclovir | |
| WO1993015716A1 (en) | Levamisole or tetramisole based pour-on formulations | |
| JPH07238021A (ja) | 皮膚刺激作用のない製薬用軟膏及びその製造方法 | |
| JPS5931709A (ja) | ９−（２−ヒドロキシエトキシメチル）グアニンを含有する浸透性局所製薬組成物 | |
| TH181A (th) | การจัดสูตรผสมของสารประกอบเฮเทอโรไซลิค |